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Abstract
Cardiac ischaemia-reperfusion (I/R) injury has been attributed to stress signals arising 
from an impaired mitochondrial electron transport chain (ETC), which include redox 
imbalance, metabolic stalling and excessive production of reactive oxygen species 
(ROS). The alternative oxidase (AOX) is a respiratory enzyme, absent in mammals, that 
accepts electrons from a reduced quinone pool to reduce oxygen to water, thereby 
restoring electron flux when impaired and, in the process, blunting ROS production. 
Hence, AOX represents a natural rescue mechanism from respiratory stress. This study 
aimed to determine how respiratory restoration through xenotopically expressed 
AOX affects the re-perfused post-ischaemic mouse heart. As expected, AOX sup-
ports ETC function and attenuates the ROS load in post-anoxic heart mitochondria. 
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1  | INTRODUC TION
The high susceptibility of cardiomyocytes to oxygen deprivation has 
been originally attributed to their almost exclusive dependence on 
oxidative metabolism for ATP production.1 Indeed, approximately 
30% of the cardiomyocyte's intracellular volume is occupied by 
mitochondria which harbour the electron transport chain (ETC) in 
their inner membrane. The ETC is composed of four oxidoreductase 
complexes (cI-cIV) that facilitate substrate oxidation and electron 
transfer with oxygen being the final acceptor. Importantly, electron 
transfer is coupled to the generation of a proton-electrochemical 
potential gradient across the inner mitochondrial membrane, which 
itself is the driving force for ATP production, a process described 
as oxidative phosphorylation (OXPHOS). Although the ETC thus 
couples ATP production to oxygen consumption, pioneering work in 
isolated rabbit heart mitochondria2 as well as in intact rabbit hearts3 
revealed that cardiac ATP depletion alone is insufficient to account 
for all post-ischaemic tissue damage.2 Instead, electron flow through 
the ETC upon reperfusion was described as a source of potentially 
detrimental reactive oxygen species (ROS), proposed to trigger isch-
aemia-reperfusion (I/R) injuries.2 Conversely, the therapeutic use 
of untargeted antioxidants such as vitamin C for post-ischaemic 
cardioprotection has given contradictory results,4-9 and itself pro-
duced detrimental side effects when therapeutically used.10 These 
seemingly contradictory results were thought to be due to biphasic 
effects of ROS with high ROS concentrations leading to damage and 
lower concentrations eliciting adaptive responses.11,12 The term 'mi-
tohormesis' was proposed13 to describe this phenomenon. Indeed, a 
recent study demonstrated that increased ROS levels specifically in 
the mitochondrial compartment have a cardioprotective effect upon 
I/R.14 Of course, it could equally be possible that untargeted antiox-
idants cannot reach sufficient levels in the mitochondrial compart-
ment to be effective, and therefore fail to detoxify mitochondrial 
ROS at the site of its production. Furthermore, ROS may generate 
positive or negative effects in a time-dependent manner.
To test this assumption, a number of mitochondrial-targeted 
antioxidants have been designed. MitoQ, one prominent example, 
consists of ubiquinol (reduced quinone) targeted specifically to mito-
chondria by a covalently fused lipophilic triphenyl phosphonium (TPP) 
cation.15 Importantly, in rats that underwent cardiac I/R, MitoQ, but 
not the untargeted antioxidant or TPP alone, significantly decreased 
contractile dysfunction, cell death and mitochondrial damage.15 
Positive effects of MitoQ were also seen in other studies addressing 
post-transplantation injury16 and pressure overload-induced heart 
failure.17 Following a similar rationale, Szeto-Schiller (SS) peptides18 
were used, which accumulate in mitochondria in a membrane poten-
tial-independent manner. The use of SS peptides caused phenotypic 
improvements in a model of angiotensin II-induced mitochondrial 
ROS production and myocardial contractile failure19 as well as upon 
transverse-aortic constriction.20 Both, MitoQ and SS peptides ap-
peared biologically safe and beneficial when long-term adminis-
tered21,22 arguing that intramitochondrial ROS are rather detrimental 
than physiologically relevant. Finally, using high-throughput chemical 
screening, small molecules that suppress superoxide and/or hydrogen 
peroxide production at the IQ site of cI were identified, S1QELs,
23 that 
act through a mechanism that does not affect regular OXPHOS. Most 
importantly, ROS generated at IQ was discussed to be instrumental 
for cellular stress signalling. Indeed, application of S1QELs protected 
the perfused mouse heart from I/R injuries.23 A unifying mechanism 
by which the different mitochondrially targeted antioxidants may ful-
fil their beneficial effects was recently put forward.24 According to 
this, succinate, an intermediate metabolite of the tricarboxylic acid 
cycle, accumulates during cardiac ischaemia.25 Reperfusion evokes 
rapid succinate oxidation through reverse electron transport (RET) 
from ubiquinol to cI concomitant with a burst of mitochondrial ROS. 
Scavenging RET-induced ROS may therefore be the mechanism by 
which cellular and organ damage is prevented although other sources 
of ROS, that are intrinsically linked, may play a signalling role as well.26
Plants and many other organisms, but not insects or vertebrates, 
harbour a by-pass mechanism to protect from ETC-mediated respi-
ratory stress conditions, the alternative oxidase (AOX).27 AOX is a 
non-protonmotive single di-iron carboxylate redox transfer protein.28 
Where expressed, AOX oxidizes ubiquinol and by-passes cIII and cIV, 
directly transferring electrons to oxygen. In previous studies, we were 
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However, post-ischaemic cardiac remodelling over 3 and 9 weeks was not improved. 
AOX blunted transcript levels of factors known to be up-regulated upon I/R such as 
the atrial natriuretic peptide (Anp) whilst expression of pro-fibrotic and pro-apoptotic 
transcripts were increased. Ex vivo analysis revealed contractile failure at nine but 
not 3 weeks after ischaemia whilst label-free quantitative proteomics identified an in-
crease in proteins promoting adverse extracellular matrix remodelling. Together, this 
indicates an essential role for ETC-derived signals during cardiac adaptive remodelling 
and identified ROS as a possible effector.
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able to show that a xenotopically expressed AOX from the tunicate 
Ciona intestinalis (hereafter called AOX) is catalytically active under 
various experimental conditions. In human cells, AOX conferred re-
sistance against the ETC inhibitor cyanide29 and corrected genetic 
defects which caused ETC dysfunction.30 In fruit flies, AOX comple-
mented ETC defects in vivo and restored viability.31 Global expres-
sion in the mouse protected against cyanide toxicity32,33 decreased 
lethality from endotoxemia34 and alleviated cigarette smoke-induced 
lung remodelling and cell death.35 AOX was demonstrated to effec-
tively decrease RET-induced ROS36,37 driven by succinate. Most im-
portantly, however, expression of AOX prevented the development 
of a lethal cardiomyopathy in a cIII mouse mutant strain38 indicating 
sufficient expression for full respiratory restoration in the stressed 
heart. Interestingly, in a mouse model of inflammatory cardiomyop-
athy,39 AOX expression in cardiomyocytes conferred detrimental ef-
fects.40 This suggests a role for the mitochondrial respiratory chain in 
both, energy homeostasis and stress signalling.
Here, we tested how maintaining electron flow impacts on re-
modelling in the post-ischaemic mouse heart. We show that AOX 
expression supports ETC function and decreases mitochondrial ROS 
levels, yet impairs adaptive cardiac remodelling. This indicates an es-
sential role for ETC-derived stress signals in post-ischaemic cardiac 
adaptation.
2  | MATERIAL S AND METHODS
2.1 | Animal models
Mice with ubiquitous expression of Ciona intestinalis AOX33 were 
maintained on a C57BL/6J background in temperature- and hu-
midity-controlled facilities at 12 hours of light-to-dark cycles with 
access to water and food ad libitum. Open-chest in situ I/R proce-
dures were conducted at the University of Cambridge, Cambridge, 
UK upon approval by Home Office license 70/8238. In vivo I/R 
procedures were conducted at the Max Planck Institute for Heart 
and Lung Research in Bad Nauheim, Germany upon approval by the 
Regierungspräsidium Darmstadt (V54-19c20/15-B2/1014).
2.2 | Open-chest in situ I/R mouse model and 
estimation of infarct size and zone at risk
Details of the procedure have been published elsewhere.14,41 
Briefly, WT and AOX transgenic littermates were anesthetized 
and ventilated with ambient air supplemented with oxygen (peak 
inspiratory pressure of 10 mbar and positive end-expiratory pres-
sure of 3 mbar) throughout the experiment. The ventilation set-
tings were adjusted to a frequency of 110 hubs per minutes and 
a tidal volume of 200-250 µL. Left anterolateral thoracotomy was 
performed to visualize the mouse heart and lay open the left an-
terior descending artery (LAD). The LAD was then surrounded by 
a 7-0 nylon suture to form a snare. After a 15 minutes period of 
stabilization, the I/R procedure was started with 30 minutes of 
ischaemia followed by 2 hour reperfusion. After the I/R proce-
dure, the LAD was re-occluded and Evans blue was injected ret-
rogradely through the aortic root. Evans blue staining was used 
to demarcate the zone of ischaemia hereafter referred to as the 
region at risk zone. After staining, hearts were excised, perfused 
with 0.9% saline solution, frozen and transversely cut into 1 mm 
slices. The slices were incubated in 1% triphenyltetrazolium chlo-
ride (TTC) in sodium phosphate buffer (pH 7.4) and incubated at 
38°C for 20 minutes. TTC stains the viable (non-infarcted myocar-
dium) brick-red based on catalytic dehydrogenase activity. Finally, 
the slices were immersed in 10% formalin and areas of infarct and 
risk zone determined slice by slice using planimetry.
2.3 | In vivo I/R mouse model
Male WT and AOX littermates received 0.1 mg/kg bodyweight 
buprenorphine s.c. prior to anaesthesia to minimize postoperative 
pain. For anaesthesia induction, mice were exposed to 4.5 Vol% 
isoflurane in ambient air for approximately 3 minutes in an air-tight 
box. Anaesthesia was maintained after intra-tracheal intubation 
and ventilation using 1.5 Vol% isoflurane using the rodent MiniVent 
ventilator (Harvard Apparatus, HSE) adjusted to 225 hubs per min-
utes with a tidal volume of 250 µL. During the procedure, animals 
were kept in a supine position on a heat-controlled plate at 37°C. A 
left anterolateral thoracotomy was performed between the second 
and third rib to visualize the mouse heart and lay open the LAD. The 
LAD was ligated in a proximal position using a 7-0 prolene suture. 
Pale discoloration of ventricular tissue demarcated the region of is-
chaemia. After ligation, animals received 5 IU of Heparin-Natrium 
s.c. and the open wound was covered using cheese cloth soaked 
with 0.9% NaCl solution. After 45 minutes of ischaemia, the ligation 
was opened and cardiac reperfusion confirmed by visual control. 
The wound was closed using absorbable, synthetic 5-0 vicryl (pol-
yglactin 910) sutures. Weaning from ventilation took several min-
utes and was ended when spontaneous respiration became evident.
2.4 | Langendorff perfusion experiments
Hearts were isolated from mice, and procedures to measure cardiac 
functions were performed as previously described.42 Briefly, after 
deep anaesthesia with isoflurane (5%), hearts were excised from 
the chest cavity, transferred rapidly to ice-cold saline and imme-
diately mounted on the cannula of Langendorff perfusion system. 
Heart perfusion and all next steps were done at 37°C. Perfusion of 
hearts was performed with perfusate (in mmol/L: NaCl 118, KCl 4.7, 
KH2PO4 1.2, KCl 2.5, MgSO4 0.8, NaHCO3 25, glucose 5, C3H3NaO3 
1.9, CaCl2 2.5). Perfusate flow was adjusted to a perfusion pressure 
of 70 mm Hg. To determine left ventricular pressure, a balloon was 
inserted into the left ventricle and inflated at 10 mm Hg. Ischaemia 
was initiated by flow stop.
4  |     SZIBOR et al.
2.5 | Respirometry and ROS production using 
isolated mitochondria
Mitochondria were isolated from cardiac tissue as described previ-
ously.43 Mitochondrial oxygen consumption and ROS production were 
measured using an Oroboros O2k oxygraph (Oroboros Instruments) 
at 37°C. Standard experimental set-up was 200 µg of mitochondrial 
protein per mL of mitochondrial respiration buffer (120 mmol/L KCl, 
1 mmol/L EGTA, 10 mmol/L HEPES, 5 mmol/L KH2PO4, pH 7.2; Sigma, 
P5405, E3889, H3375, P5655) along with 30 μL of 1 mg/mL superoxide 
dismutase (Sigma, S5395), 30 µL of 1 mg/mL horseradish peroxidase 
(Sigma, 77332), 30 µL of 10 mg/mL fatty acid-free-BSA (Sigma, A6003) 
and 5 µL of Amplex Red Reagent (ThermoFisher, A12222) for hydrogen 
peroxide detection. Mitochondrial respiration was initiated by the ad-
dition of 10 mmol/L succinate (Sigma, S3674). To confirm AOX activity, 
1 mmol/L cyanide (KCN, Sigma, 60178) was added to both WT and AOX 
mitochondria, prior to AOX inhibition by 100 μM n-propyl gallate (Sigma, 
P3130). To assess hydrogen peroxide production as the consequence of 
RET, mitochondrial respiration was stimulated by the addition of suc-
cinate and respiration allowed to diminish all oxygen present within the 
chamber. Once anoxic, mitochondria were left for 20 or 30 minutes to 
simulate ischaemia, after which oxygen was allowed back into the cham-
ber and oxygen consumption and ROS production measured. To assess 
sole AOX activity, cyanide was added at the start of the experiment.
2.6 | Western blot analysis
Western blots were performed essentially as described elsewhere.44 
Rabbit serum raised against two AOX peptides (anti-AOX, 1:20 000, 
21st Century Biochemicals)30 and mouse monoclonal antibody 
against the voltage-dependent anion channel (anti-VDAC1, 1:1000, 
Abcam ab14734) were used and protein bands were visualized 
using a LI-COR Odyssey flatbed scanner with anti-mouse and anti-
rabbit secondary antibodies conjugated to IRDye 680RD and IRDye 
800CW, respectively.
2.7 | Respirometry using skinned heart fibres and 
heart tissue homogenate
Mitochondrial respiratory activity upon in vivo I/R was measured 
using skinned fibre isolation (3-weeks I/R) as described in detail else-
where45,46 or after homogenization of heart tissue using a POLYTRON 
PT 1200 E Manual Disperser (Ecoline; 9-weeks I/R). For skinned fibre 
isolation, left-ventricular heart tissue was dissected on ice in a plas-
tic cell-culture dish using extra sharp forceps to extract thin muscle 
fibres. These fibres were permeabilized for 30 minutes using sapo-
nin (50 µg/mL) as previously described.45,46 Upon washing, fibres 
were dried on Whatman paper and weighted before transfer to the 
oxygraph chamber. For heart tissue homogenization, left-ventricular 
heart tissue was weighted and then minced on ice using scissors and 
a POLYTRON homogenizer before transfer to the oxygraph chamber. 
Using either technique, mitochondria were found to be accessible for 
substrates and inhibitors, and exhibited coupled respiration albeit at 
different activity levels per mg of the respective sample. Oxygen con-
sumption was measured using Oroboros O2k oxygraphs (Oroboros 
Instruments, Innsbruck, Austria)47 at 30°C calculated from the time 
derivative of the oxygen concentration using DatLab 7 software 
(Oroboros Instruments, Innsbruck, Austria). 1-2 mg of fibre/tissue 
homogenate was added per chamber to respiration buffer containing 
120 mmol/L D-mannitol (Sigma-Aldrich, M4125), 20 mmol/L MOPS 
(Sigma, M1254), 5 mmol/L KH2PO4 (Sigma, P5655), 60 mmol/L KCl, 
5 mmol/L MgCl2, pH7.4. Substrates used for cI-driven respiration 
(PGM plus ADP): 10 mmol/L pyruvate (P, Sigma, P5280), 10 mmol/L 
glutamate (G, Aldrich, 49621), 2 mmol/L malate (M, Sigma, M1000) 
and adenosine 5′-diphosphate (ADP, Sigma, A2754). Substrates used 
for cIV measurements: 2 mmol/L (+)-sodium L-ascorbate (Asc, Sigma, 
A7631) and 0.5 mmol/L N,N,N′,N′-tetramethyl-p-phenylenediamine 
(TMPD, Sigma, T7394). Respiratory inhibitors used for control: 
1.5 µmol/L rotenone (Sigma-Aldrich, R8875), 5 mmol/L sodium 
azide (Sigma-Aldrich, S2002), 1 mmol/L cyanide (Sigma, 60178) and 
100 µmol/L n-propyl gallate (Sigma, P3130).
2.8 | RNA extraction, reverse transcription 
(RT) and qPCR
Total RNA was extracted from left ventricles by RNeasy Micro Kit 
(Qiagen). The extracted RNA was reverse-transcribed (RT) to cDNA 
using iScript cDNA Synthesis Kit (Bio-Rad). qPCR was done using 
iTaq SYBR Green Supermix with ROX (Bio-Rad) and Mx3000P qPCR 
System (Agilent Technologies). All measurements were carried out 
in duplicate. Melting curves confirmed desired products formation. 
The calculation of ΔCt values was done by subtracting the Ct val-
ues of the target gene from the endogenous control [ΔCt = Ct (en-
dogenous control) − Ct (target)]. Transcript expression levels as fold 
change were calculated from 2−ΔΔCt. B2m (β2 microglobulin) served as 
a reference housekeeping gene.
Gene Forward primer Reverse primer
B2m GCTATCCAGAAAACCCCTCAA CATGTCTCGATCCCAGTAGACGGT
Anp GGCTCCTCCCTCGTCTTGG GCTTCCTCAGTCTGCTCAC
Col1a1 TTCTCCTGGAAAGATGGTGC GGACCAGCATCACCTTTAACA
Col3a1 CTTTCCCGGTGGGCGTGGTC TGAGCACCAGGTGGCCCCTT
Sod2 GACTATGGCGCGCTGGAGCC TCCCTTGGCCAGAGCCTCGT
Ucp2 GGCCTCTGGAAAGGGACTTC GACCACATCAACAGGGGAGG
Bax TACAGGGTTTCATCCAGG ATTGCTATCCAGCCTATCTC
Bcl2 TCGCAGAGATGTCCAGTC CCCACCGAACTCAAAGAAG
2.9 | Transmission electron microscopy
A small piece of tissue from the heart apex was kept in storage buffer 
containing 1.5% glutaraldehyde, 1.5% formaldehyde, 0.15 mol/L 
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HEPES/KOH (pH 7.4) at 4°C until embedding and sectioning. For 
epoxy resin embedding, samples were fixed in 1% osmium tetroxide, 
stained en bloc in half-saturated uranyl acetate, dehydrated in an as-
cending ethanol series and embedded in Agar 100 (Agar Scientific). 
Ultra-thin sections were cut using an ultramicrotome (Reichert 
Ultracut E, Leica) and examined in a transmission electron micro-
scope (Zeiss EM 902). Digital images were captured with a slow-scan 
2K CCD camera (TRS, Tröndle, Moorenweis, Germany).
2.10 | Nano LC-MS/MS and data analysis
Mouse heart samples were homogenized using a FastPrep-24 5G 
High Speed Homogenizer (MP Biomedicals). Tissue pieces were 
transferred to 2 mL tubes with Lysing matrix D, and 750 µL 8 mol/L 
urea (Sigma, U5378) in 50 mmol/L NH4HCO3 (Sigma, A6141) and pro-
tease inhibitor mix (cOmplete ULTRA Tablets, 05892970001, Roche 
Applied Science) were added. Homogenization was done with five 
cycles of 30 seconds 6 m/s pulses and had 5 minutes break on ice in 
between the cycles. After homogenization, the protein concentra-
tion was measured using NanoDrop, and a volume corresponding to 
200 µg protein was used for further analysis. Proteins were reduced 
with dithiothreitol (DTT, Sigma, D9779), alkylated with iodoaceta-
mide (Sigma, I6125) and in-solution digested with LysC (2 hours at 
room temperature, Wako, 125-05061) and trypsin (overnight at 
room temperature, Promega, V5111).
The resulting peptides were desalted and concentrated before 
mass spectrometry using µC18 tip (Pierce C18 Tips). The peptides were 
eluted with 0.1% trifluoroacetic acid (TFA, Merck, 0.08260.0101) in 
60% acetonitrile (ACN, Merck, 1.00029.2500), dried and solubilized in 
7 μL 0.1% formic acid (FA, Merck, 1.59013.2500) for mass spectrom-
etry analysis. Each peptide mixture was analysed on an Easy nLC1000 
nano-LC system connected to a quadrupole Orbitrap mass spec-
trometer (QExactive, ThermoElectron, Bremen, Germany) equipped 
with a nano-electrospray ion source (EasySpray, Thermo). For the 
liquid chromatography separation of the peptides, an EasySpray col-
umn capillary of 25 cm bed length was employed. The flow rate was 
300 nL/min, and the peptides were eluted with a 2%-30% gradient of 
solvent B in 240 minutes. Solvent A was aqueous 0.1% FA and solvent 
B 0.1% FA in acetonitrile. The data-dependent acquisition automati-
cally switched between MS and MS/MS mode. Survey full scan MS 
spectra were acquired from a mass-to-charge ratio (m/z) of 400 to 
1200 with the resolution R = 70 000 at m/z 200 after accumulation to 
a target of 3 000 000 ions in the quadruple. For MS/MS, the ten most 
abundant multiple-charged ions were selected for fragmentation on 
the high-energy collision dissociation cell at a target value of 100 000 
charges or maximum acquisition time of 100 ms The MS/MS scans 
were collected at a resolution of 17 500. Target ions already selected 
for MS/MS were dynamically excluded for 30 seconds.
The resulting MS raw files were submitted to the MaxQuant soft-
ware (version 1.5.7.4)48 for protein identification and quantitation 
using the Andromeda search engine. MaxQuant search was done 
against the UniProt mouse database (March 2017). Carbamidomethyl 
(C) was set as a fixed modification and protein N-acetylation and me-
thionine oxidation were set as variable modifications. First search 
peptide tolerance of 20 ppm and main search error 4.5 ppm were 
used. Trypsin without proline restriction enzyme option was used, 
with two allowed miscleavages. The minimal unique + razor peptides 
number was set to 1 and the allowed false discovery rate (FDR) was 
0.01 (1%) for peptide and protein identification. Label-free quan-
tification (LFQ) was done with default settings in MaxQuant. The 
mass spectrometry proteomics data have been deposited to the 
ProteomeXchange49 Consortium via the PRIDE50 partner reposi-
tory with the dataset identifier: PXD014061 and the project name 
‘Expression of Ciona intestinalis AOX in a mouse model of cardiac 
ischemia-reperfusion’.
2.11 | Statistical analyses
Statistical analyses, except for proteome, were performed using 
GraphPad Prism (GraphPad Software, version 7 for Mac OS X). 
1way or 2way ANOVA and post hoc analyses were used as indicated 
for comparisons of at least n = 3 independent experiments, and a 
P value <.05 was considered being statistically significant. All data 
are shown as mean. Error bars represent standard error of the mean 
(SEM). Proteome analysis was done using Perseus software (version 
1.6.1.3).51 LFQ values were log2 transformed and filtered to include 
only proteins identified and quantified in at least three out of five 
replicates in at least one experimental group, and missing values 
were imputed with values representing background from a normal 
distribution with default settings in Perseus. To find statistically sig-
nificant differences between the sample groups Student's t test was 
done with a P value of <.05 being considered statistically significant.
3  | RESULTS
3.1 | AOX does not decrease acute I/R injuries
Succinate accumulation during cardiac ischaemia25 is one pro-
posed trigger for RET-mediated ROS production24 and supposedly 
I/R-mediated injury. AOX was previously demonstrated to blunt 
RET-induced ROS production under various conditions.33,34,36,37 
We therefore first tested whether the extent of acute I/R injury 
(infarct size) would be decreased in the post-ischaemic heart of 
mice with excellent cardiac AOX protein expression and catalytic 
AOX activity.33 Using the open-chest in situ I/R model,41 30 min-
utes of ischaemia were applied by occluding the left anterior de-
scending (LAD) coronary artery followed by 2 hours of reperfusion 
in wild-type (WT) and AOX littermates. The infarct size was esti-
mated as a percentage scar tissue of the risk zone.41,52 As shown in 
Figure 1A,B, AOX expression did not confer any benefit. We next 
sought to investigate whether the heart might nevertheless benefit 
during the early post-ischaemic phase through improved functional 
recovery of surviving myocytes and analysed heart contractile 
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functions ex vivo in the isolated, perfused (Langendorff) heart. 
Upon 45 minutes of ischaemia, WT and AOX hearts showed nearly 
indistinguishable systolic (P syst, Figure 1C) and diastolic (P diast, 
Figure 1D) pressure-response curves. Furthermore, calculated left 
ventricular developed pressures (LVDP [maximal systolic–diastolic 
pressure]) (Figure 1E) and heart rate*pressure products (RPP, a 
surrogate value of cardiac work)53 (Figure 1F) revealed no differ-
ence. Of note, hearts typically develop a rigour during ischaemia. 
This manifests as an increase in pressure during the ischaemic in-
sult and, in our experience, correlates closely with the infarct size. 
WT and AOX hearts developed the same degree of rigour during 
ischaemia (Figure 1D) once again being indicative for a lack AOX-
mediated cardioprotection during I/R.
3.2 | AOX is catalytically active in post-anoxic heart 
mitochondria
One possible explanation for the observed failure of protection could 
be insufficient AOX expression or its catalytic impairment in the 
F I G U R E  1   AOX does not protect the heart from I/R injury. A, B, Open-chest in situ mouse heart model with 30 min ischaemia and 2 h 
reperfusion. A, Representative images of infarcts from WT and AOX mice as indicated. Blue, Evans blue staining indicates perfused tissue; 
brick-red, TTC converted to precipitate indicates viable post-ischaemic tissue; white, indicates scar tissue; brick-red and white together form 
the 'region of risk' zone. B, Infarct size depicted as % of region at risk zone. Data shown as mean ± SEM of n = 6 experiments. C-F, Response 
curves from the ex vivo isolated perfused Langendorff heart model with 45 min ischaemia (red area) and 30 min reoxygenation. C, Systolic 
pressure (P syst); D, diastolic pressure (P diast); E, left ventricular developed pressure (LVDP); F, heart rate*pressure product (RPP). Pre, 
control values at time point 0. All Langendorff data are shown as mean ± SEM of n ≥ 8 experiments
A B
C D
E F
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post-ischaemic heart. To test this possibility, we isolated mitochondria 
from WT and AOX mouse hearts and measured oxygen consumption 
and ROS production in vitro, and, importantly, confirmed a robust 
expression of AOX by Western blot (Figure S1A). As expected, AOX 
supported succinate-driven respiration in a cyanide-resistant manner 
(Figure 2A) at ambient oxygen concentrations. AOX-driven cyanide-re-
sistant respiration was associated with the prevention of mitochondrial 
hydrogen peroxide production (Figure 2B). Next, we tested whether 
AOX catalytic activity depends on a certain oxygen concentration. In 
other words, we sought to test if AOX loses its catalytic activity under-
neath a critical threshold of oxygen availability such as seen in the is-
chaemic heart. We thus measured oxygen consumption and hydrogen 
peroxide production under different oxygen concentrations ranging 
from ~21% (ambient air) to full anoxia (Figure 2C,D). We found that the 
oxygen consumption in AOX heart mitochondria was slightly higher 
than in WT across a broad range of oxygen concentrations (Figure 2C). 
Hydrogen peroxide production showed a linear relationship with oxy-
gen availability in WT and was lower in AOX mitochondria (Figure 2D). 
To simulate the situation in the post-ischaemic heart, we challenged 
heart mitochondria by a 20 minutes period of anoxia (simulated is-
chaemia, Figure 2E,F). Using this approach, oxygen consumption in 
WT heart mitochondria was slightly higher than in those from AOX 
hearts, at all oxygen concentrations (Figure 2E). In contrast, hydrogen 
peroxide production, which again showed a linear relationship with 
oxygen availability, was significantly lower in AOX heart mitochon-
dria (Figure 2F). To rule out the possibility that the period of anoxia 
was not sufficient, we replicated the experiments with an extended 
period of anoxia (30 minutes), which essentially gave the same results 
(Figure S1B-E). Together with previous findings of AOX activity in the 
heart under various conditions,33,38,40 we concluded that a functional 
F I G U R E  2   AOX is catalytically 
engaged in post-anoxic heart 
mitochondria and lowers mitochondrial 
ROS production. A-F, Isolated WT and 
AOX heart mitochondria energized with 
cII substrate succinate and addition of 
inhibitors as indicated. KCN, cIV inhibitor 
potassium cyanide; nPG, AOX inhibitor 
n-propyl gallate. A, Oxygen consumption. 
B, Hydrogen peroxide production. Data 
in (A, B) are shown as mean ± SEM of 
n ≥ 3 experiments. Horizontal bars in 
(A, B) indicate significant differences 
with P < .05 analysed by 1way ANOVA 
and Tukey's multiple comparisons test. 
C, Oxygen consumption in dependence 
of oxygen concentration. D, Hydrogen 
peroxide production in dependence 
of oxygen concentration. E, Oxygen 
consumption during reoxygenation after 
20 min of anoxia. F, Hydrogen peroxide 
production during reoxygenation after 
20 min of anoxia. Data in (C-F) are shown 
as mean ± SEM of n ≥ 3 experiments. Grey 
areas and vertical bars indicate significant 
differences with P < .05 analysed by 2way 
ANOVA and Tukey's multiple comparisons 
test in (C, D) and Sidak's multiple 
comparisons test in (F)
A B
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impairment of AOX is an unlikely explanation for the lack of cardiopro-
tection against I/R injury, and that, therefore, all observed phenomena 
can mechanistically be attributed to catalytic AOX activity interfering 
with the mitochondrial respiratory chain and specifically to the resto-
ration of the electron flux through the ETC.
3.3 | AOX improves mitochondrial functions 
3 weeks after an ischaemic insult
We hypothesized that the restoration of electron flux by AOX and 
supposed decrease in RET-induced ROS, despite the lack of a meas-
urable advantage during the acute phase, might yet be beneficial for 
the post-ischaemic remodelling process. We tested this assumption 
in WT and AOX mice 3 weeks after a transient (45 minutes) ischae-
mic insult followed by restoration of blood flow (reperfusion).54 
Functional left-heart parameters (P syst and LVDP) measured ex 
vivo, however, revealed no significant difference between WT and 
AOX (Figure 3A,B). Conversely, high-resolution respirometry using 
permeabilized heart fibres revealed that cI-linked respiration, driven 
by pyruvate, glutamate and malate (PGM) plus ADP (Figure 3C), as 
well as cIV activity driven by ascorbate/TMPD (Figure 3D) was sig-
nificantly compromised in WT I/R but not AOX I/R hearts. The find-
ing that cIV was impaired in WT I/R hearts came unexpected, since 
cIV lies downstream of the quinone pool and the ROS-producing 
complexes cI and cIII. Interestingly, electron microscopy revealed no 
evidence for an ultrastructural correlate of these biochemical dif-
ferences, for example at the level of mitochondrial cristae density 
(Figure S2).
Typically, adaptive cardiac response to hemodynamic or meta-
bolic stress is seen as myocardial hypertrophy concomitant with and 
triggered by an alteration of gene expression. To determine whether 
respiratory restoration by AOX induced a shift in gene expression in 
response to the ischaemic insult, we measured transcript levels of 
common marker genes. First, we measured that of the atrial natri-
uretic peptide (Anp), which is recognized as both a biomarker for the 
diagnosis of heart failure as well as a prognostic marker for cardio-
vascular risk.55 Expression of the Anp was significantly increased by 
F I G U R E  3   AOX expression does not affect cardiac contractility in vivo 3 wk after I/R despite improved respiratory function. A, B, Left 
ventricular pressures built up ex vivo in the isolated perfused Langendorff heart model of WT and AOX hearts subjected to 45 min of 
ischaemia or SHAM operation followed by 3 wk of reperfusion and remodelling in vivo. Data shown as mean ± SEM of n ≥ 6 experiments. 
A, Systolic pressure (P syst); B, left ventricular developed pressure (LVDP). C, D, Oxygen consumption of isolated skinned heart fibres. Data 
shown as mean ± SEM of n ≥ 4 experiments. C, Complex I (cI) activity driven by combinations of pyruvate (P), glutamate (G) and malate (M) as 
indicated, plus ADP. Horizontal bars indicate significant differences with P < .05 analysed by 2way ANOVA and Tukey's multiple comparisons 
test. D, Complex IV (cIV) activity driven by ascorbate (Asc) and N,N,N′,N′-tetramethyl-p-phenylenediamine (TMPD). Horizontal bars indicate 
significant differences with P < .05 analysed by 1way ANOVA and Tukey's multiple comparisons test
A B
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I/R in WT hearts but, importantly, this increase was blunted in AOX 
animals (Figure 4A). Since ANP has been described as profibrogenic56 
and since excess cardiac collagen synthesis and deposition is known 
to negatively affect contractile function,57 we measured transcripts 
of collagen 1 (Col1a1) and 3 (Col3a1), which we found specifically in-
creased in the AOX I/R group (Figures 4B,C). We also looked at the 
expression of mitochondrial genes involved in the response to oxi-
dative stress. Superoxide dismutase 2 (Sod2) is a mitochondrial protein 
that detoxifies superoxide generated as by-product of OXPHOS, by 
converting it to hydrogen peroxide and molecular oxygen. Sod2 is 
induced as part of the cell-inherent ROS stress response,58 which, 
when lacking, induces cardiac malfunctioning.59 Transcript levels of 
Sod2 appeared down-regulated in AOX hearts compared with WT, 
irrespective of any intervention (Figure 4D). Uncoupling proteins 
(UCPs), in contrast, are mitochondrial inner membrane proteins 
that act as proton leaks, thereby dissipating the proton gradient. 
Uncoupling protein 2 (Ucp2) has previously been shown to be instru-
mental for protection against pressure overload-induced right heart 
failure.60 Here, we found Ucp2 specifically up-regulated in the AOX 
I/R group (Figure 4E). Finally, heart failure due to apoptotic loss of 
cardiomyocytes has been long discussed.61 Bcl-2-associated X pro-
tein (BAX) is a pro-apoptotic member of the BCL2 protein family. 
Indeed, Bax transcript expression has been negatively correlated 
with cardiac function whilst Bcl2 transcript expression has positive 
effects.62 More specifically, an increased Bax/Bcl2 ratio has been 
seen in cardiac fibrosis.63 Of note, we found a significant increase in 
the ratio of Bax to Bcl2 (Figure 4F-H), which is indicative for a cellular 
shift towards a pro-apoptotic phenotype.
3.4 | AOX impairs cardiac contractility 9 weeks 
after an ischaemic insult
The lack of any positive impact on post-ischaemic functioning, de-
spite the prevention of Anp transcript induction, prompted us to 
investigate the effects of AOX at a later time point. Nine weeks 
after transient ischaemia (45 minutes), ex vivo functional meas-
urements revealed a significant decrease in P syst (Figure 5A) and 
LVDP (Figure 5B) specifically in the AOX I/R group. High-resolution 
respirometry revealed a continuing, albeit much smaller, cI defect 
F I G U R E  4   Relative transcript levels 
in total RNA from WT and AOX hearts 
subjected to 45 min of ischaemia or 
SHAM operation followed by 3 wk of 
reperfusion and remodelling in vivo, 
normalized to B2m (β2 microglobulin), a 
reference housekeeping gene. Data shown 
as mean ± SEM of n ≥ 6 experiments. 
Horizontal bars indicate significant 
differences with P < .05 analysed by 1way 
ANOVA and Tukey's multiple comparisons 
test. A, Atrial natriuretic peptide (Anp); 
B, Collagen 1 (Col1a1); C, Collagen 3 
(Col3a1); D, Superoxide dismutase 2 (Sod2); 
E, Uncoupling protein 2 (Ucp2); F, Bcl2-
associated X (Bax); G, B-cell lymphoma 2 
(Bcl2); H, Bax/Bcl2 expression ratio
A B C
D E
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in WT I/R but not in AOX I/R hearts (Figure 5C) whilst cIV activ-
ity was fully restored (Figure 5D). At this later time point, Anp tran-
script levels were even more elevated in WT I/R hearts than 3 weeks 
after ischaemia and AOX again prevented Anp induction (Figure 6A). 
Most other alterations of transcript level were less pronounced 
(Figure 6B-H).
3.5 | AOX fosters extracellular matrix remodelling 
in the post-ischaemic heart
To shed light on the mechanisms that may underlie the post-ischae-
mic functional deterioration of AOX I/R hearts, we initiated an unbi-
ased, label-free quantitative proteome approach (data submitted to 
PRIDE database, identifier PXD014061) and used GOrilla, an online 
tool designed to discover and visualize enriched gene ontologies in 
ranked lists64,65 (Tables S1 and S2). We revealed a pronounced ex-
pression of proteins involved in the reorganization of the extracellu-
lar matrix as a major feature in the post-ischaemic AOX heart. This is 
best exemplified by the expression of the protein periostin (POSTN, 
osteoblast-specific factor). Periostin was up-regulated almost five-
fold in post-ischaemic compared with SHAM-operated AOX hearts 
at 3 weeks, and 17-fold at 9 weeks, whilst the increase in the cor-
responding WT hearts was <2- and approximately sevenfold after 3 
and 9 weeks, respectively.
4  | DISCUSSION
In the present study, we tested how respiratory restoration by 
AOX affects the development of I/R injury and adaptive remodel-
ling in the mouse heart. Our data demonstrate that AOX, despite 
being sufficiently expressed and catalytically active in the healthy 
and diseased mouse heart,33,38,40 fails to confer either acute or 
chronic cardioprotection, despite respiratory restoration. Instead, 
AOX expression fosters long-term adverse remodelling and car-
diac contractile impairment. Since one effect of AOX should be 
a decrease in mitochondrial superoxide production, the outcome 
of this study may seem surprising. Previous studies using mito-
chondrially targeted antioxidants under ostensibly comparable 
conditions did result in cardioprotection, as discussed in detail 
elsewhere.66 Although ischaemic accumulation of succinate was 
shown to be instrumental for reperfusion injury through RET-
induced ROS production25 and despite recent findings that AOX 
can specifically decrease RET34,36,37 the outcome of this study may 
be in accordance with another proposed mechanism, namely mito-
hormesis.13 For instance, AOX may suppress mitochondrial signals, 
for example ROS, to a degree that adaptive cardiac remodelling is 
impaired. Indeed, a cardioprotective effect of low ROS levels has 
been shown.14 Conversely, it may be that AOX, which like cIV re-
quires oxygen as terminal electron acceptor, becomes only slowly 
F I G U R E  5   AOX expression decreases cardiac contractility 9 wk after I/R. A, B, Left ventricular pressures built up ex vivo in the isolated 
perfused Langendorff heart model of WT and AOX hearts subjected to 45 min of ischaemia or SHAM operation and 9 wk of reperfusion/ 
remodelling. Data shown as mean ± SEM of n ≥ 4 experiments. Horizontal bars in (A) and (B) indicate significant differences with P < .05 
analysed by 1way ANOVA and Tukey's multiple comparisons test. A, Systolic pressure (P syst); B, left ventricular developed pressure (LVDP). 
C, D, Oxygen consumption of heart tissue homogenate. Data shown as mean ± SEM of n = 3 experiments. C, Complex I (cI) activity driven by 
pyruvate (P), glutamate (G) and malate (M) plus ADP. Horizontal bars indicate significant differences with P < .05 analysed by 2way ANOVA 
and Tukey's multiple comparisons test. D, Complex IV (cIV) activity driven by ascorbate (Asc) and N,N,N′,N′-tetramethyl-p-phenylenediamine 
(TMPD)
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reactivated upon tissue reoxygenation. In such a case, cI and/or 
cIII may produce excess amounts of detrimental ROS in a small 
post-ischaemic time-window before AOX can exert any protective 
effect. However, our in vitro data indicate that AOX is catalyti-
cally engaged both before and after simulated ischaemic insults 
and prevents RET-induced ROS production under the conditions 
experienced in the post-ischaemic heart.36,37 This would argue 
against a role for slow reactivation. Furthermore, respirometry 
after 3 weeks of reperfusion revealed that AOX did confer some 
protection from respiratory impairment, specifically of cI and cIV, 
despite the lack of any functional improvement. This makes a limi-
tation on AOX catalytic activity in the post-ischaemic heart an un-
likely explanation for the observed lack of acute cardioprotection.
One fundamental difference between the use of antioxi-
dants targeted to mitochondria and genetically expressed AOX 
is that the former are not normally replenished beyond the acute 
post-ischaemic phase. In addition, antioxidants, unlike AOX, may 
exhibit antioxidant effects during transit to the mitochondria and 
may therefore not be entirely specific for mitochondrial ROS. An 
obvious follow-up study to test this idea would be the use of an 
inducible AOX strain to enable transient AOX expression during 
different phases of the I/R procedure. The use of AOX as a ther-
apeutic, in the form of an mRNA mimetic or recombinant protein, 
may also address this issue. Both approaches would nevertheless 
suffer other shortcomings such as time- and/or organ-unspecific 
expression of relevant drivers, unwanted side effects of the same 
drivers in case of the genetic approach, and immune and inflamma-
tory responses in case of the therapeutic use of AOX, necessitating 
cumbersome controls.
Despite its ability to maintain respiration and dampen RET-induced 
ROS in isolated mitochondria, we found that AOX not only fails to pro-
vide cardioprotection but actually promotes post-ischaemic maladap-
tation. An interesting aspect of our study is that the presence of AOX 
in the post-ischaemic heart restores cI-driven respiration. In fact, cI 
may be both, a ROS-producing complex for instance under conditions 
as seen in the post-ischaemic heart24,25 or itself a target for ROS dam-
age.67 Previously, however, it was shown that supplementing rat hearts 
undergoing ischaemic insults with Ndi1, a single-subunit protein that in 
Saccharomyces cerevisiae serves as an NADH dehydrogenase, greatly 
decreases I/R injury and infarct size.68,69 In the light of this and of our 
F I G U R E  6   Relative transcript levels 
in total RNA from WT and AOX hearts 
subjected to 45 min of ischaemia or 
SHAM operation followed by 9 wk of 
reperfusion and remodelling in vivo, 
normalized to B2m (β2 microglobulin), a 
reference housekeeping gene. Data shown 
as mean ± SEM of n = 8 experiments. 
Horizontal bars indicate significant 
differences with P < .05 analysed by 1way 
ANOVA and Tukey's multiple comparisons 
test. A, Atrial natriuretic peptide (Anp); 
B, Collagen 1 (Col1a1); C, Collagen 3 
(Col3a1); D, Superoxide dismutase 2 (Sod2); 
E, Uncoupling protein 2 (Ucp2); F, Bcl2-
associated X (Bax); G, B-cell lymphoma 2 
(Bcl2); H, Bax/Bcl2 expression ratio
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findings showing that AOX can restore cI-driven respiration whilst de-
creasing ROS, it seems reasonable to conclude that other factors than 
ROS production or electron flow restoration through cI must contrib-
ute to the cardiac stress response.
The present findings have some similarity with another study in 
which AOX was found to disrupt skeletal muscle remodelling upon 
knock-out of cIV assembly factor COX15, a protein involved in the 
biosynthetic pathway of mitochondrial haem A, a prosthetic group of 
cIV.58 In this model, co-expression of AOX exacerbated muscle dys-
function and accelerated premature death. The aggravated muscle 
phenotype was associated with decreased mitochondrial biogenesis 
and, most likely, impaired progenitor (satellite) cell recruitment. Due 
to the absence of cardiac progenitor cells, other mechanisms must be 
considered in the mouse heart, although the underlying mechanism, a 
failure of regular stress signalling and repair processes, may be similar. 
Our study also recapitulates a study showing that mitochondria-tar-
geted overexpression of catalase does not prevent cardioskeletal my-
opathy in a mouse model of Barth syndrome.70 It is important to note, 
however, that whilst catalase facilitates the turnover of hydrogen per-
oxide to water and oxygen, AOX prevents the production of superox-
ide at the impaired ETC and thus acts far upstream.
To provide some indication of the mechanism whereby AOX leads 
eventually to a maladaptive cardiac remodelling, we studied the ex-
pression of a small set of marker genes. Although the findings do not 
provide a definitive explanation, they reveal valuable clues that should 
be followed up by a more detailed characterization of the physiolog-
ical and molecular changes in the AOX I/R model, as now discussed. 
First, AOX abrogated the up-regulation of Anp at the transcript level. 
ANP was originally found to be up-regulated in the failing heart, irre-
spective of the underlying cause71 and was assumed to be compensa-
tory in nature.72 This view has subsequently been challenged.73 ANP 
is now considered a diagnostic marker of maladaptive cardiac remod-
elling.55,74-77 This notion may need further revision, in the light of our 
finding of increased expression of Col1a1 and Col3a1 in AOX hearts, 
despite the blunted Anp response. Whilst collagen decreases wall 
stress, it also impairs contractile function due to increased stiffness, 
and accompanies the development of heart failure.57
One consequence of Anp signalling, shown previously in rat 
pulmonary arterial smooth muscle cells, is the inhibition of TGFβ-
induced extracellular matrix components.78 We suggest that this 
might account for the observed up-regulation of periostin, consistent 
with another study where heart remodelling upon stress was asso-
ciated with progressive extracellular matrix remodelling.79 However, 
the role of periostin in cardiac repair remains unclear: whilst it has 
been found to initiate cell cycle re-entry of adult cardiomyocytes 
upon stress80 it is also associated with myocardial fibrosis in some 
forms of heart failure.81-83 Consistent with the idea that AOX inter-
feres with a respiratory stress signal related to mitochondrial ROS, 
we observed downregulation of the oxidative stress marker Sod2, 
but up-regulation of Ucp2, previously observed in conditions of car-
diovascular stress.84
In conclusion, we infer that mitochondrial respiratory restoration 
and the presumed decrease of mitochondrial ROS by AOX in the 
post-ischaemic heart are not sufficient to confer cardioprotection. 
Instead, AOX expression interferes with adaptive organ remodelling 
leading to contractile failure, implying an essential role for ETC-
derived stress signals in this process.
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